Bio-Thera And BeiGene Partner For Bevacizumab In China
Partnered Territory Includes Hong Kong, Macau and Taiwan
Bio-Thera is collaborating with BeiGene for BAT1706, a biosimilar to Avastin (bevacizumab), to develop, manufacture and commercialize the product in Greater China.
You may also be interested in...
China’s Bio-Thera has struck a licensing deal with Biomm that will give the Brazilian company exclusive rights to market the BAT1706 bevacizumab biosimilar in its home market.
China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.
Continuing parent firm Gilead’s busy deal-making year in immuno-oncology, Kite gets option rights to new targets. Boehringer teams with Israel’s BiomX in IBD research.